BR0207689A - Preparação, e, método de preparação de ligando de receptor de ah endógeno - Google Patents

Preparação, e, método de preparação de ligando de receptor de ah endógeno

Info

Publication number
BR0207689A
BR0207689A BR0207689-6A BR0207689A BR0207689A BR 0207689 A BR0207689 A BR 0207689A BR 0207689 A BR0207689 A BR 0207689A BR 0207689 A BR0207689 A BR 0207689A
Authority
BR
Brazil
Prior art keywords
preparation
receptor ligand
endogenous
preparing
preparing endogenous
Prior art date
Application number
BR0207689-6A
Other languages
English (en)
Inventor
Hector F Deluca
Jiasheng Song
Margaret Clagett-Dame
Richard E Peterson
William M Westler
Raphal R Sicinski
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BR0207689A publication Critical patent/BR0207689A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"PREPARAçãO, E, MéTODO DE PREPARAçãO DE LIGANDO DE RECEPTOR DE Ah ENDóGENO". Revela-se a preparação, o uso, e a estrutura de ligando de receptor de Ah endógeno.
BR0207689-6A 2001-02-14 2002-02-12 Preparação, e, método de preparação de ligando de receptor de ah endógeno BR0207689A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26880901P 2001-02-14 2001-02-14
PCT/US2002/004137 WO2002064138A1 (en) 2001-02-14 2002-02-12 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester

Publications (1)

Publication Number Publication Date
BR0207689A true BR0207689A (pt) 2004-03-09

Family

ID=23024571

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207689-6A BR0207689A (pt) 2001-02-14 2002-02-12 Preparação, e, método de preparação de ligando de receptor de ah endógeno

Country Status (13)

Country Link
US (1) US6916834B2 (pt)
EP (1) EP1365760B1 (pt)
JP (1) JP4509478B2 (pt)
AT (1) ATE431823T1 (pt)
AU (1) AU2002248422B2 (pt)
BR (1) BR0207689A (pt)
CA (1) CA2437579C (pt)
DE (1) DE60232403D1 (pt)
ES (1) ES2327615T3 (pt)
IL (2) IL157301A0 (pt)
MX (1) MXPA03007245A (pt)
NZ (1) NZ527430A (pt)
WO (1) WO2002064138A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE394373T1 (de) * 2002-02-12 2008-05-15 Wisconsin Alumni Res Found Synthese von indolthiazolverbindungen als liganden des ah-rezeptors
AU2003267773A1 (en) * 2003-10-14 2005-04-27 Council Of Scientific And Industrial Research (3r, 4r)-trans-3,4-diarylchroman derivatives with estrogenic activity
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
EP3689347A1 (en) * 2009-11-02 2020-08-05 Ariagen, Inc. Ite for cancer intervention and eradication
CN102775399A (zh) * 2011-12-27 2012-11-14 盛世泰科生物医药技术(苏州)有限公司 arylhydrocarbon受体(AHR)的内源性配体,2-(1’H3’-吲哚羰基)噻唑-4-羧酸甲酯的合成新方法
CN107001350B (zh) 2014-09-12 2021-04-09 阿里根公司 2-(1’h-吲哚-3’-羰基)-噻唑-4-羧酸甲酯及其结构类似物的有效且可扩展的合成
CN108239083B (zh) * 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
JP2021503498A (ja) * 2017-11-20 2021-02-12 アリアジェン，インコーポレイテッド アリール炭化水素受容体（ａｈｒ）調節剤としてのインドール化合物
US20210347794A1 (en) 2018-09-21 2021-11-11 Ariagen, Inc. Phosphate Derivatives of Indole Compounds and Their Use
WO2020106695A1 (en) * 2018-11-19 2020-05-28 Ariagen, Inc. Methods of treating cancer
JP2022528977A (ja) 2019-04-15 2022-06-16 アリアジェン，インコーポレイテッド キラルインドール化合物およびその使用
US11136318B2 (en) 2019-06-21 2021-10-05 Noramco, Llc Processes for the preparation of aryl hydrocarbon receptor ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3285931A (en) * 1964-12-21 1966-11-15 Union Carbide Corp Preparation of substituted pyrrole derivatives
GB9215361D0 (en) * 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
US5336685A (en) * 1993-04-12 1994-08-09 Sloan-Kettering Institute For Cancer Research Use of flavonoids to treat multidrug resistant cancer cells
US6323228B1 (en) * 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
ATE394373T1 (de) * 2002-02-12 2008-05-15 Wisconsin Alumni Res Found Synthese von indolthiazolverbindungen als liganden des ah-rezeptors

Also Published As

Publication number Publication date
ATE431823T1 (de) 2009-06-15
ES2327615T3 (es) 2009-11-02
MXPA03007245A (es) 2004-06-30
WO2002064138A1 (en) 2002-08-22
DE60232403D1 (de) 2009-07-02
EP1365760A1 (en) 2003-12-03
IL157301A0 (en) 2004-02-19
EP1365760B1 (en) 2009-05-20
US6916834B2 (en) 2005-07-12
US20020183524A1 (en) 2002-12-05
CA2437579C (en) 2012-05-01
CA2437579A1 (en) 2002-08-22
NZ527430A (en) 2005-03-24
JP4509478B2 (ja) 2010-07-21
JP2004527482A (ja) 2004-09-09
EP1365760A4 (en) 2004-07-14
AU2002248422B2 (en) 2006-07-06
IL157301A (en) 2012-03-29

Similar Documents

Publication Publication Date Title
BR0207689A (pt) Preparação, e, método de preparação de ligando de receptor de ah endógeno
EE05387B1 (et) KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine
TR200602095T2 (tr) Hümanize Anti-LT-Beta-R antikorları
DK1392164T3 (da) Fremgangsmåde til opnåelse af geometriske data med hensyn til øregangen i det menneskelige legeme
WO2005009928A3 (en) Preparation and use of alkylating agents
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
NO20024838D0 (no) Salter av bicykliske, N-acylerte imidazo-3-aminer og imidazo- 5-aminer
EA200400399A1 (ru) Способы лечения легочных заболеваний
AU2003260513A1 (en) Polyclonal antibodies, preparation method thereof and use of same
TR200102742T2 (tr) Rezorsinol türevleri
NO20015634D0 (no) Fremgangsmåte for tilveiebringelse av tjenester
ID28430A (id) Peningkatan jaringan dengan menggunakan informasi geolokasi
ITRM20000266A0 (it) Procedimento migliorato per la preparazione di (e,z) 3-(2-amminoetossimmino)-androstano-6, 17-dione e di suoi analoghi.
IS2331B (is) 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra
PT1228056E (pt) Metodo de preparacao de citaloprame
EE200100305A (et) Preparaat, selle kasutamine ja valmistamismeetod
BR0316544A (pt) Compostos calcilìticos
PT1448566E (pt) Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
DK1407038T3 (da) Thermostabil isomerase og anvendelse deraf, specielt til fremstilling af tagatose
DE69930733D1 (de) Herstellung von substituierten (amino)alkoxysilanen
EA200601030A1 (ru) 7α,17α-ЗАМЕЩЁННЫЕ 11β-ГАЛОГЕНОСТЕРОИДЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ НА ИХ ОСНОВЕ
DE60208365D1 (de) Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln
DE60220699D1 (de) Tibolonformulierungen
IT1312105B1 (it) Procedimento per ottenere pentafluoroetano per dismutazione daclorotetrafluoroetano

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]